illustration of a laptop surrounded by data visualization plots
Opinion: In Defense of Preprints
In response to two November 2021 articles in The Scientist that called out preprints as a source of medical misinformation, the cofounders of bioRxiv and medRxiv say it’s not the publishing model that’s at fault.
ABOVE: © ISTOCK.COM, NATALYABUROVA
Opinion: In Defense of Preprints
Opinion: In Defense of Preprints

In response to two November 2021 articles in The Scientist that called out preprints as a source of medical misinformation, the cofounders of bioRxiv and medRxiv say it’s not the publishing model that’s at fault.

In response to two November 2021 articles in The Scientist that called out preprints as a source of medical misinformation, the cofounders of bioRxiv and medRxiv say it’s not the publishing model that’s at fault.

ABOVE: © ISTOCK.COM, NATALYABUROVA

hydroxychloroquine

Illustration depicting peers reviewing a paper
Opinion: The Problem with Preprints
Michael Mullins | Nov 1, 2021
Preprints can be valuable additions to the scientific literature. But we must start seeing them as perishable commodities rather than akin to peer-reviewed, published studies.
a pill bottle with dice spilling out
Book Excerpt from You Bet Your Life
Paul A. Offit | Sep 21, 2021
In his book’s Introduction, physician-scientist Paul A. Offit reviews the unusual constellation of circumstances around the development of COVID-19 vaccines.
a gavel with a pipet and wellplate
Elisabeth Bik Faces Legal Action After Criticizing Studies
Shawna Williams | May 28, 2021
A complaint lodged by researchers in France prompts two petitions supporting Bik’s whistleblowing work.
retraction publishing science surgisphere the lancet nejm hydroxychloroquine
The Top Retractions of 2020
Retraction Watch | Dec 15, 2020
The Retraction Watch team takes a look at the most important publishing mistakes this year.
The Lancet Alters Editorial Practices After Surgisphere Scandal
Catherine Offord | Sep 22, 2020
The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.
FDA Pulls Emergency Use Authorization for Antimalarial Drugs
Amanda Heidt | Jun 16, 2020
Hydroxychloroquine and chloroquine, once thought to be promising COVID-19 treatments, come with serious heart risks.
Exclusive
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Catherine Offord | May 30, 2020
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.
WHO Halts Hydroxychloroquine Testing Over Safety Concerns
Catherine Offord | May 27, 2020
A paper published in The Lancet reported that hospitalized COVID-19 patients taking the drug had a higher risk of death, although some researchers have raised questions about the data.
chloroquine hydroxychloroquine covid-19 sars-cov-2 coronavirus trump didier raoult
Journal Publisher Concerned over Hydroxychloroquine Study
Kerry Grens | Apr 9, 2020
The report by Didier Raoult and colleagues that examined the use of the anti-malarial drug in a small number of COVID-19 patients receives criticism from the very society that published it.
chloroquine hydroxychloroquine covid-19 coronavirus sars-cov-2 malaria antimalarial antiviral
Chloroquine for COVID-19: Cutting Through the Hype
Chris Baraniuk | Mar 20, 2020
President Donald Trump has touted the drug as a treatment but scientists still don’t know for sure that it is effective in patients. A number of clinical trials aim to find out.